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Abstract 
Recent reports linking Down syndrome (DS) to maternal polymorphism at the methylenetetrahydrofolate dehydrogenase 
(MTHFD) locus have generated a great interest among investigators in the field. In the current study, we examine one genetic 
polymorphism involved in homocysteine/folate pathway as a risk factor for DS in a Romanian urban-area women cohort. Our results 
show that the frequencies of MTHFD1 alleles, as well as the frequencies of MTHFD11958 genotypes (GG, GA, AA, GA+AA) do not 
correlate with DS pregnancies, demonstrating no difference between the case and control groups, as opposed to the findings of 
Scala et al. (2006) on an Italian cohort. 
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Introduction 
Down syndrome (DS) is a genetic disease 
resulting from the presence and expression of three 
copies of the genes located on chromosome 21. In 95% 
of DS cases, the nondisjunction of chromosome 21 
occurs during meiosis I in the maturing oocyte; although 
advanced maternal age represents the major risk factor 
for DS, most children with this complex metabolic disease 
are born to young mothers (less than 35 years) [1]. The 
mechanism underlying the meiotic nondisjunction is 
poorly understood and is thought to have a multifactorial 
aetiology, being influenced by both genetic and acquired 
factors [2,3].  
Abnormal folate metabolism and common folate-
metabolizing enzyme variants have been described as 
possible risk factors for DS [2,4]. A deficiency in cellular 
folates (members of the B9 vitamins family) and methyl 
donors may be associated with abnormal DNA 
methylation, DNA strand breaks, defective chromosome 
recombination, and abnormal chromosome segregation 
[5,6,7,8].  The folate cycle is involved in two essential 
physiological processes: the synthesis of purines and 
pyrimidines required for DNA synthesis and repair; and 
the methylation associated with the methionine cycle. 
Lower levels of folate have been associated with 
increased risks of trisomy 21 and therefore, folic acid 
supplemental intake is now commonly recommended 
during pre- and post-conception and early pregnancy. 
Methylenetetrahydrofolate dehydrogenase, 
MTHFD is an enzyme involved in folate metabolism, a 
trifunctional protein that mediates the interconversion of 
5,10-MTHF, 5,10-methenylTHF, and 10-formylTHF. The 
last two are the donor cofactors for de novo purine and 
pyrimidine biosynthesis and, thus, for the biosynthesis of 
DNA [9]. 
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The MTHFD1 gene is located on chromosome 
14 (14q24). A common MTHFD1 1958G>A polymorphism 
(Arg653Gln) reduces the enzyme’s activity and stability 
and has been associated with an increased risk of several 
human diseases, including neural tube defects, congenital 
heart defects and unexplained second semester 
pregnancy loss [10,11,12]. 
Our paper addresses the relationship between 
MTHFD1 1958G>A polymorphism and the risk of DS 
pregnancy in a Romanian urban-area cohort of women. 
Materials and methods 
Our study included 26 women who gave birth to 
DS babies and 46 control mothers of healthy children. 
The case mothers were interviewed and a questionnaire 
regarding age, place of residency (rural/urban) during the 
pregnancy period, education, obstetric history, and 
periconceptional folic acid intake was completed. The DS 
mothers were younger than 40 years old and 7 of them 
had a history of spontaneous miscarriages (26.92%). In 
all cases, their babies were confirmed of having classic 
trisomy 21. The control blood samples were collected 
from 46 women who gave birth only to healthy children, 
without any history of miscarriages or abnormal 
pregnancies. An informed consent was obtained from all 
participants. All women in our study reside in the same 
geographic area and have a similar social background.  
Peripheral blood samples (5 ml) were collected 
on EDTA from all participants. Genomic DNA was isolated 
from the whole blood by using PeqGOLD Blood DNA mini 
kit, while following the manufacturer’s instructions.  
The presence of MTHFD1 1958G>A mutation 
was analyzed by polymerase chain reaction followed by a 
restriction fragment length polymorphism analysis - allele 
specific restriction digestion with MspI (PCR-RFLP). 
Primers for amplification were forward: 5’-
CCTGGTTTCCACAGGGCACTC-3’ and reverse 5’-
CCACGTGGGGGCAGAG GCCGGAATACCGG-3’. PCR 
conditions were denaturation 94°C (1 minute), annealing 
60°C (1 minute), elongation 72°C (1minute) for a total of 
36 cycles. The PCR amplification generated a 310 bp 
fragment. The transition observed in MTHFD1 1958G>A 
variant abolishes a MspI restriction site; therefore after 
MspI digestion of the PCR product, the A-allele was 
detected by the presence of 282 and 28 bp fragments, 
while the G-allele was identified by the presence of 196, 
86 and 28 bp fragments. 
 
Statistical Analysis 
Allele frequencies were calculated for each 
genotype, and the differences in allele frequencies 
between mothers of children with DS and control mothers 
were determined by using a chi-square test. Expected 
genotype frequencies were calculated from the allele 
frequencies under the assumption of Hardy-Weinberg 
equilibrium. The interaction between the two MTHFD1 
genotypes was evaluated by calculating the odds ratios 
and p values for mutant genotypes. The analyses were 
performed while using the SPSS software. 
Results and discussions 
In this study, we examined one polymorphism in 
methylenetetrahydrofolate dehydrogenase (MTHFD1) - 
gene encoding a folate-metabolizing enzyme - as a 
maternal risk factor for meiotic nondisjunction of 
chromosomes 21, causing DS, in a cohort of Romanian 
mothers. The investigation of the polymorphism was 
addressed by PCR amplification of genomic DNA by 
using the primers described in Materials and Methods 
section, followed by restriction digestion with an 
appropriate endonuclease. The results of the mutational 
analysis are shown for a few representative cases in the 
(Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As observed in fig. 2, following PCR-RFLP 
analysis, cases 3 and 43 have the homozygous 1958AA 
genotype, cases 26 and 27 –homozygous 1958GG 
genotype and cases 7 and 22 – heterozygous 1958 AA 
genotype. 
 
 
 
Genotype  Allele           DS mothers (%)          Control mothers (%)    2    p value 
1958  G  29(55.76%)  55(59.78%)  0.22  0.63 
  A  23(44.23%)  37(40.22%)     
  Total  52  92     
Fig 2 PCR-RFLP (Msp1) mutational analysis of MTHFD 
1958G>A polymorphism. Lane 1 – case 3; 2 – case 7; 3 – 
case 22 ; 4 – case 26; 5–case 27; 6– case 43; M – pGEM 
100 bp molecular weight marker (Promega). 
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The allele frequencies of MTHFD1 1958G>A in 
DS mothers and control mothers are listed in table 1. 
MTHFD1  1958 A allele frequency was 44.23 % in DS 
mothers (χ2: 0.22, p value 0.63). 
 
 
 
 
Genotype       DS mothers (%)    Control mothers (%)   Odds ratio      95% CI    p value 
GG  6 (23.07%)  15 (32.60%)  1  Reference   
GA  17 (65.38%)  25 (54.34%)  1.7  0.54-5.26  0.35 
AA  3 (11.53%)  6 (13.04%)  1.25  0.23-6.69  0.79 
GAorAA  20 (76.92%)  31 (67.39%)  1.61  0.53-4.85  0.39 
 
As far as genotypic frequencies are concerned, 
GA heterozygous genotype frequencies of MTHFD1 at 
position 1958 were higher among DS mothers than 
among controls mothers (65.38 % versus 54.34 % with an 
odds ratio of 1.7 (95% confidence interval (CI) 0.54-5.26) 
indicating that this polymorphism may have a genetic 
impact upon the risk of DS. AA homozygous genotype 
frequency at this position was higher in control mothers 
than in DS mothers (13.04 % versus 11.53 % 
respectively, with an odds ratio of 1.25 (95% CI 0.23 to 
6.69), although not at a statistically significant level.  
Several studies performed in the last decade 
suggest a possible contribution of an impaired folate 
metabolism to MTHFD1 DS risk, and the current opinion 
is that the presence of mutant alleles in the genome might 
affect the risk of the disease. However, the studies 
performed so far, have often provided conflicting results 
[13,14,15,16] and the question is still unsolved. Certainly, 
trisomy 21 is the result of the interplay of several factors 
of genetic, epigenetic, environmental and stochastic 
origin; in this context all the studies performed so far 
[13,14,15,16] have provided some putative DS risk 
factors. 
Scala et al. investigated the possible contribution 
of the MTHFD1 1958G>A polymorphism as a maternal 
risk factor for having a DS child and observed positive 
interactions for the combined MTHFD1  1958AA/RFC1 
80GG genotype [17]. We investigated the prevalence of 
the MTHFD1 genotype variation in Romania, in our study, 
finding the frequencies of the GG, GA and AA genotypes 
at 1958 position among DS mothers of 23.07 %, 65.38 %, 
and 11.53 %, respectively, and among control mothers - 
of 32.60 %, 54.34 %, and 13.04 %, respectively. These 
data do not point to any association between the 
polymorphisms as this locus and the risk of having DS 
infants, in contrast with the previous study. 
 Conclusions 
We did not find any statistically significant 
association between MTHFD1 polymorphic genotype and 
the history of DS pregnancies; thus, the relationship 
between MTHFD1 polymorphism and DS appears to be 
only a supposition and the next step in our study is the 
catamnestic evaluation of our patients with DS babies for 
two years. Additional studies are essential to unravel the 
complex relationship between genes, micronutrients, and 
folate/methyl metabolism. 
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